DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Leggas M, Adachi M, Scheffer GL, et al. MRP4 confers
resistance to topotecan and protects the brain from
chemotherapy. Mol Cell Biol, 2004, 24:7612–7621.
Lesch KP, Bengel D, Heils A, et al. Association of anxietyrelated
traits with a polymorphism in the serotonin transporter
gene regulatory region. Science, 1996, 274:1527–1531.
Leslie E, Deeley R, Cole S. Multidrug resistance proteins:
role of P-glycoprotein, MRP1, MRP2 and BCRP (ABCG2)
in tissue defense. Toxicol Appl Pharmacol, 2005, 204:216–
237.
Li C, Krishnamurthy PC, Penmatsa H, et al. Spatiotemporal
coupling of cAMP transporter to CFTR chloride channel
function in the gut epithelia. Cell, 2007, 131:940–951.
Lin JH, Yamazaki M. Clinical relevance of P-glycoprotein in
drug therapy. Drug Metab Rev, 2003, 35:417–454.
Locher KP, Lee AT, Rees DC. The E.coli BtuCD structure: A
framework for ABC transporter architecture and mechanism.
Science, 2002, 296:1091–1098.
Matsushima S, Maeda K, Ishiguro N, et al. Investigation of the
inhibitory effects of various drugs on the hepatic uptake of
fexofenadine in humans. Drug Metab Dispos, 2008, 36:663–
669.
Matsushima S, Maeda K, Kondo C, et al. Identification of the
hepatic efflux transporters of organic anions using doubletransfected
Madin-Darby canine kidney II cells expressing
human organic anion-transporting polypeptide 1B1 (OATP1B1)/
multidrug resistance-associated protein 2, OATP1B1/multidrug
resistance 1, and OATP1B1/breast cancer resistance protein.
J Pharmacol Exp Ther, 2005, 314:1059–1067.
Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. Impact of drug
transporter studies on drug discovery and development.
Pharmacol Rev, 2003, 55:425–461.
Mori S, Takanaga H, Ohtsuki S, et al. Rat organic anion
transporter 3 (rOAT3) is responsible for brain-to-blood efflux
of homovanillic acid at the abluminal membrane of brain
capillary endothelial cells. J Cereb Blood Flow Metab, 2003,
23:432–440.
Murphy DL, Lerner A, Rudnick G, Lesch KP. Serotonin
transporter: Gene, genetic disorders, and pharmacogenetics.
Mol Interven, 2004, 4:109–123.
Mwinyi J, Johne A, Bauer S, et al. Evidence for inverse effects
of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin
kinetics. Clin Pharmacol Ther, 2004, 75:415–421.
Naesens M, Kuypers DRJ, Verbeke K, Vanrenterghem Y.
Multidrug resistance protein 2 genetic polymorphisms
influence mycophenolic acid exposure in renal allograft
recipients. Transplantation, 2006, 82:1074–1084.
Nezu J, Tamai I, Oku A, et al. Primary systemic carnitine
deficiency is caused by mutations in a gene encoding sodium
ion–dependent carnitine transporter. Nature Genet, 1999,
21:91–94.
Niemi M, Backman JT, Kajosaari LI, et al. Polymorphic organic
anion transporting polypeptide 1B1 is a major determinant of
repaglinide pharmacokinetics. Clin Pharmacol Ther, 2005,
77:468–478.
Niemi M, Schaeffeler E, Lang T, et al. High plasma pravastatin
concentrations are associated with single nucleotide
polymorphisms and haplotypes of organic anion transporting
polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics,
2004, 14:429–440.
Ocheltree SM, Shen H, Hu Y, et al. Mechanisms of cefadroxil
uptake in the choroid plexus: Studies in wild-type and PEPT2
knockout mice. J Pharmacol Exp Ther, 2004, 308:462–467.
Okuda M, Saito H, Urakami Y, et al. cDNA cloning and
functional expression of a novel rat kidney organic cation
transporter, OCT2. Biochem Biophys Res Commun, 1996,
224:500–507.
Olivier B, Soudijn W, van Wijngaarden I. Serotonin, dopamine
and norepinephrine transporters in the central nervous system
and their inhibitors. Prog Drug Res, 2000, 54:59–119.
Oostendorp RL, Buckle T, Beijnen JH, et al. The effect of P-gp,
BCRP and P-gp/BCRP inhibitors on the in vivo absorption,
distribution, metabolism and excretion of imatinib. Invest New
Drugs, 2008, 27:31–40.
Osato DH, Huang CC, Kawamoto M, et al. Functional
characterization in yeast of genetic variants in the human
equilibrative nucleo-side transporter, ENT1. Pharmacogenetics,
2003, 13:297–301.
Ose A, Ito M, Kusuhara H, et al. Limited brain distribution of
[3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-
cyclohexene-1-carboxylate phosphate (Ro 64-0802), a
pharmacologically active form of oseltamivir, by active efflux
across the blood-brain barrier mediated by organic anion
transporter 3 (OAT3/SLC22A8) and multidrug resistanceassociated
protein 4 (MRP4/ABCC4). Drug Metab Dispos,
2009, 37:315–321.
Otsuka M, Matsumoto T, Morimoto R, et al. A human transporter
protein that mediates the final excretion step for toxic organic
cations. Proc Natl Acad Sci USA, 2005, 102:17923–17928.
Pascual JM, Wang D, Lecumberri B, et al. GLUT1 deficiency
and other glucose transporter diseases. Eur J Endocrinol,
2004, 150:627–633.
Paulusma CC, Bosma PJ, Zaman GJ, et al. Congenital jaundice
in rats with a mutation in a multidrug resistance-associated
protein gene. Science, 1996, 271:1126–1128.
Pinkett HW, Lee AT, Lum P, et al. An inward-facing
conformation of a putative metal-chelate-type ABC
transporter. Science, 2006, 315:373–377.
Polli JW, Olson KL, Chism JP, et al. An unexpected synergist
role of P-glycoprotein and breast cancer resistance protein on
the CNS penetration of the tyrosine kinase inhibitor lapatinib
(GW572016). Drug Metab Dispos, 2009, 37:439–442.
Rader, D.J. Regulation of reverse cholesterol transport and
clinical implications. Am J Cardiol, 2003, 92:42J–49J.
Rader DJ. Molecular regulation of HDL metabolism and
function: Implications for novel therapies. J Clin Invest, 2006,
116:3090–3100.
Reuss L. Basic mechanisms of ion transport. In, The Kidney:
Physiology and Pathophysiology (Seldin D, Giebisch G,
eds.), Lippincott Williams & Wilkins, Baltimore, 2000, pp.
85–106.
Sadee W, Drubbisch V, Amidon GL. Biology of membrane
transport proteins. Pharm Res, 1995, 12:1823–1837.
Sadeque AJ, Wandel C, He H. Increased drug delivery to the
brain by P-glycoprotein inhibition. Clin Pharmacol Ther,
2000, 68:231–237.
Sasaki M, Suzuki H, Ito K. Transcellular transport of organic
anions across a double-transfected Madin-Darby canine
kidney II cell monolayer expressing both human organic
anion-transporting polypeptide (OATP2/SLC21A6) and
119
CHAPTER 5
MEMBRANE TRANSPORTERS AND DRUG RESPONSE